NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM
Updated: Feb 10
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04772989
Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
First Posted : February 26, 2021
Click here to see details on ClinicalTrials.gov
Drug: AB308
Anti-TIGIT Monoclonal Antibody AB308 (Code C179552)
AB 308
AB-308
AB308
Anti-TIGIT Monoclonal Antibody AB308
Drug: Zimberelimab, AB122
Zimberelimab (Code C159549)
AB 122
AB-122
AB122
Anti-PD-1 Monoclonal Antibody GLS-010
GLS 010
GLS-010
GLS010
WBP-3055
Zimberelimab
ZIMBERELIMAB
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Florida
United States, Georgia
United States, Indiana
United States, Iowa
United States, Kentucky
United States, Michigan
United States, Minnesota
United States, New York
United States, Ohio
United States, Oklahoma
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Utah
United States, Virginia
United States, Wisconsin